Unique ID issued by UMIN | UMIN000011728 |
---|---|
Receipt number | R000013711 |
Scientific Title | Effect of irbesartan,angiotensin 2 receptor antagonist(ARB)for urinary marker of the hypertensive patients |
Date of disclosure of the study information | 2013/09/12 |
Last modified on | 2015/09/15 08:05:34 |
Effect of irbesartan,angiotensin 2 receptor antagonist(ARB)for urinary marker of the hypertensive patients
Effect of irbesartan,angiotensin 2 receptor antagonist(ARB)for urinary marker of the hypertensive patients
Effect of irbesartan,angiotensin 2 receptor antagonist(ARB)for urinary marker of the hypertensive patients
Effect of irbesartan,angiotensin 2 receptor antagonist(ARB)for urinary marker of the hypertensive patients
Japan |
Hypertensive patients
Medicine in general | Nephrology |
Others
NO
Give ARB(irbesartan) to hypertensive patients;blood pressure control,urinary marker(urine protein fixed-quantity,urinary L-FABP)of the renal function disorder improvement Liver type fatty acid-binding protein,urinary NAG;N-acetyl-beta-D-glucosamidase,urinary alfa 1-MG;alfa 1-microglobulin,urinary beta 2-MG;beta 2-microglobulin),and a review deserve it in possibility og new treatment in the practical medical treatment
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
Change of the marker in the urinary for 12 weeks,24weeks,and 48 weeks (urinary L-FABP,urinary NAG,urinary alfa 1-MG,urinary beta 2-MG;beta 2-microglobulin)
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is not considered as adjustment factor.
YES
3
Treatment
Medicine |
When we give irbesartan 100 mg to hypertensive of the ARB or ACEI non-dosage and do not reach the aim blood pressure, we do dose increment to up to 200 mg. In the above, we gain weight and use CCB, a diuretic together appropriately when we do not reach the aim blood pressure.
We change it to irbesartan of the equivalent conversion dose for ARB, the ACE to hypertensive during ARB or the ACEI dosage. When we do not reach the aim blood pressure, we make dose increment to up to 200 mg. In the above, we gain weight and use CCB, a diuretic together appropriately when we do not reach the aim blood pressure.
When we do not reach the aim blood pressure in the hypertensive whom we did not change to irbesartan, we increase CCB, a diuretic in quantity in the above appropriately and use it together.
20 | years-old | <= |
Not applicable |
Male and Female
Hypertensive patients
1;the patient of a serious impaired liver function (AST or ALT exceeds 3 times of a normal value maximum)
2;The patient that there is not serum K in a normal level range
3;A patient with pregnancy and breast-feeding or these schedules, and possibility
4;The patient who has an allergy anamnesis to a trial drug
5;the patient who judged that a doctor was unsuitable
100
1st name | |
Middle name | |
Last name | Hiroshige Ohashi |
Murakami Memorial Hospital Asahi University
Nephrology
3-23,Hashimoto-cho,Gifu city,Gifu, 500-8523,Japan
058-253-8001
shogo-k@kanazawa-med.ac.jp
1st name | |
Middle name | |
Last name | Shogo kimura |
JA Chuno Kousei Hospital
Nephrology
5-1,wakakusa,seki city,gifu 501-3802,Japan
0575-22-2211
shogo-k@kanazawa-med.ac.jp
Murakami Memorial Hospital Asahi University
none
Self funding
NO
朝日大学附属村上記念病院(岐阜県)、JA岐阜厚生連 中濃厚生病院(岐阜県)
2013 | Year | 09 | Month | 12 | Day |
Unpublished
Completed
2013 | Year | 09 | Month | 09 | Day |
2013 | Year | 10 | Month | 01 | Day |
2014 | Year | 12 | Month | 31 | Day |
2015 | Year | 03 | Month | 31 | Day |
2013 | Year | 09 | Month | 12 | Day |
2015 | Year | 09 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013711
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |